Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Cervical cancer
Cure status
- 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)Phase 3 · NCT05056402
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)Phase 3 · NCT05056402
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)Phase 3 · NCT04422366
- 9MW2821Phase 3 · NCT06692166
- adjuvant concurrent chemoradiotherapyPhase 3 · NCT05277688
- Adjuvant radiotherapyPhase 3 · NCT04989647
- AK104Phase 3 · NCT04982237 · NCT05063916 · NCT05235516 · NCT06209294
- Albumin-Bound PaclitaxelPhase 3 · NCT05367206 · NCT06055738
- bevacizumabPhase 3 · NCT04982237 · NCT06023862 · NCT05798819 · NCT07216703 · NCT05579366 · NCT06400472 · NCT07080216 · NCT06047379 · NCT06543576 · NCT07497074 · NCT07054567
- Bivalent HPV vaccinePhase 3 · NCT04537156 · NCT02834637
- brachytherapyPhase 3 · NCT05570422 · NCT02466971 · NCT07061977 · NCT05173272 · NCT02595879 · NCT06543576 · NCT06333821
- BTPhase 3 · NCT05235516 · NCT05687851
- camrelizumab； famitinib malatePhase 3 · NCT04906993
- carboplatinPhase 3 · NCT06123884 · NCT04982237 · NCT01566240 · NCT07646301 · NCT04016389 · NCT07061977 · NCT05798819 · NCT04644068 · NCT04389632 · NCT07216703 · NCT05579366 · NCT06400472 · NCT06419673 · NCT06297811 · NCT06047379 · NCT06209294 · NCT05367206 · NCT03534713 · NCT06535607
- Carboplatin InjectionPhase 3 · NCT07168200 · NCT06859775
- CCRTPhase 3 · NCT05173272
- CisplatinPhase 3 · NCT07276360 · NCT05570422 · NCT06156514 · NCT02466971 · NCT06123884 · NCT04982237 · NCT01566240 · NCT07646301 · NCT04016389 · NCT07061977 · NCT04491942 · NCT05798819 · NCT07613567 · NCT07811375 · NCT06511726 · NCT06288360 · NCT06288373 · NCT05799469 · NCT06331468 · NCT04389632 · NCT05521997 · NCT05235516 · NCT07216703 · NCT06426056 · NCT06419673 · NCT06289751 · NCT02595879 · NCT07232654 · NCT06543576 · NCT06333821 · NCT03534713 · NCT07876154 · NCT06289062 · NCT06055738 · NCT06535607 · NCT04580771
- Cisplatin InjectionPhase 3 · NCT07168200 · NCT06859775
- cisplatin, gemcitabinePhase 3 · NCT05764044
- concurrent chemotherapyPhase 3 · NCT07439497 · NCT04583254 · NCT07400536 · NCT07709650
- Conventional ChemoradiotherapyPhase 3 · NCT07709650
- Conventional Fractionated IMRTPhase 3 · NCT06509724
- Conventional radiotherapyPhase 3 · NCT06641635
- DocetaxelPhase 3 · NCT04140526 · NCT04895709 · NCT07797153
- Dose reduction concurrent chemotherapyPhase 3 · NCT07400536
- EBRTPhase 3 · NCT05235516 · NCT05687851
- External Beam Radiation TherapyPhase 3 · NCT05570422 · NCT02466971 · NCT07061977 · NCT02595879 · NCT06543576
- External Beam Radiotherapy (EBRT)Phase 3 · NCT05799469 · NCT06333821
- Gardasil-9Phase 3 · NCT03848039
- GARDASIL®Phase 3 · NCT04422366
- GARDASIL® 9Phase 3 · NCT05662020
- GemcitabinePhase 3 · NCT06156514 · NCT06459180 · NCT06023862 · NCT03101995
- Gemcitabine (GEM)Phase 3 · NCT07797153
- Gemcitabine Hydrochloride for InjectionPhase 3 · NCT07418749
- GLS-010Phase 3 · NCT05798819
- HAV vaccinePhase 3 · NCT05173324
- HPV vaccinePhase 3 · NCT05173324
- Hypofractionated ChemoradiotherapyPhase 3 · NCT07709650
- Hypofractionated IMRTPhase 3 · NCT06509724
- Immune induction therapyPhase 3 · NCT07400536
- Immunomaintenance therapyPhase 3 · NCT07613567 · NCT07400536
- Intensity-Modulated Radiation TherapyPhase 3 · NCT02466971 · NCT07061977 · NCT02595879
- IrinotecanPhase 3 · NCT06459180
- JSKN033Phase 3 · NCT07497074 · NCT07797153
- Moderated hypofractionated online adaptive radiotherapyPhase 3 · NCT06641635
- Neoadjuvant chemoimmunotherapyPhase 3 · NCT07613567
- NimotuzumabPhase 3 · NCT06333821
- No adjuvant therapyPhase 3 · NCT04989647
- Nonavalent HPV vaccinePhase 3 · NCT04537156 · NCT02834637
- paclitaxelPhase 3 · NCT04982237 · NCT01566240 · NCT07646301 · NCT04016389 · NCT07061977 · NCT06023862 · NCT05798819 · NCT07811375 · NCT06492070 · NCT04644068 · NCT07216703 · NCT06297811 · NCT05107674 · NCT06047379 · NCT06543576 · NCT03534713 · NCT06535607
- paclitaxel and platinumPhase 3 · NCT06870565
- paclitaxel combined with platinumPhase 3 · NCT05735145
- Paclitaxel for Injection (Albumin bound)Phase 3 · NCT07418749
- Paclitaxel InjectionPhase 3 · NCT07168200
- Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiationPhase 3 · NCT04974346
- Pelvic definitive concurrent chemoradiationPhase 3 · NCT04974346
- PembrolizumabPhase 3 · NCT07749586 · NCT05082259 · NCT07061977 · NCT02628067 · NCT03589339 · NCT04865887 · NCT05438420 · NCT04389632 · NCT06640283 · NCT07223424 · NCT07227168 · NCT07216703 · NCT06266338 · NCT05579366 · NCT06400472 · NCT06465069 · NCT05269381 · NCT04485013 · NCT06047379 · NCT06543576 · NCT04140526 · NCT05081609 · NCT07218003 · NCT07770100 · NCT07054567 · NCT05581004
- PemetrexedPhase 3 · NCT06459180 · NCT07797153
- Pemetrexed Disodium for InjectionPhase 3 · NCT07418749
- platinumPhase 3 · NCT06870565 · NCT06128460 · NCT07497074
- platinum-based chemotherapyPhase 3 · NCT04906993
- Radiotherapy combined with immunotherapyPhase 3 · NCT07613567
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)Phase 3 · NCT05662020
- Reduced dose intensity of IOPhase 3 · NCT05078047
- Reduced dose radiotherapyPhase 3 · NCT07400536
- Rescue MedicationsPhase 3 · NCT07216703
- Sacituzumab TirumotecanPhase 3 · NCT06459180 · NCT07216703 · NCT07256236
- SHR-1316 InjectionPhase 3 · NCT07168200
- SHR-A2102 for InjectionPhase 3 · NCT07418749
- Socazolimab+cisplatin/carboplatin+paclitaxel+BevacizumabPhase 3 · NCT06459687
- standard EBRT+BrachytherapyPhase 3 · NCT07613567 · NCT07400536
- SYS6002Phase 3 · NCT07230626
- testosterone pellet (100 mg)Phase 3 · NCT06343870
- Tisotumab VedotinPhase 3 · NCT06459180
- TopotecanPhase 3 · NCT06459180 · NCT07797153
- Topotecan Hydrochloride for InjectionPhase 3 · NCT07418749
- TriapinePhase 3 · NCT02466971 · NCT02595879
- VinorelbinePhase 3 · NCT06459180
- VolrustomigPhase 3 · NCT06943833 · NCT06079671 · NCT06535607
- WX390 1.1mg + Toripalimab 240mgPhase 3 · NCT07392060
- Bevacizumab InjectionPhase 2/3 · NCT06123884 · NCT06859775
- CamrelizumabPhase 2/3 · NCT06288360 · NCT06288373 · NCT07627620 · NCT06289062
- Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapyPhase 2/3 · NCT03755739
- Chemotherapy and bevacizumab (CT-BEV)Phase 2/3 · NCT07472153
- cisplatin/carboplatin + paclitaxel ± bevacizumabPhase 2/3 · NCT06755515
- external beam radiation therapy (EBRT) + brachytherapyPhase 2/3 · NCT06288373
- LB1410Phase 2/3 · NCT07177716
- LB4330Phase 2/3 · NCT07177716
- LenvatinibPhase 2/3 · NCT05824468 · NCT04865887 · NCT04977453 · NCT06266338 · NCT07177716
- Nab paclitaxelPhase 2/3 · NCT06288373 · NCT06426056 · NCT06209294 · NCT06289062
- Paclitaxel for InjectionPhase 2/3 · NCT06123884
- PD-1 antibodyPhase 2/3 · NCT07472153
- PD-L1 antibodyPhase 2/3 · NCT07472153
- Photon extended field radiation therapyPhase 2/3 · NCT07298642
- Proton extended field radiation therapyPhase 2/3 · NCT07298642
- Recombinant humanized anti-PD-1 monoclonal antibody injectionPhase 2/3 · NCT06123884
- RulonilimabPhase 2/3 · NCT06755515
- 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapyPhase 2 · NCT07035808
- 3-Fraction HDR BrachytherapyPhase 2 · NCT07022470
- 4-Fraction HDR BrachytherapyPhase 2 · NCT07022470
- 5-FUPhase 2 · NCT06535607
- 5% 5-fluorouracil Topical CreamPhase 2 · NCT07545746
- Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrencePhase 2 · NCT03617133
- Adaptive Hypofractionated RadiotherapyPhase 2 · NCT07516210
- AdavosertibPhase 2 · NCT02465060
- AdebrelimabPhase 2 · NCT07811375 · NCT06149767 · NCT07731828
- AfatinibPhase 2 · NCT02465060
- Afatinib DimaleatePhase 2 · NCT02465060
- AK104 - ChemotherapyPhase 2 · NCT06998394
- AK105 and anlotinibPhase 2 · NCT05137171
- Albumin-Bound Paclitaxel /nab-PaclitaxelPhase 2 · NCT06511726
- AldesleukinPhase 2 · NCT05483491 · NCT05639972 · NCT05686226
- All-trans retinoic acidPhase 2 · NCT07586826
- AnlotinibPhase 2 · NCT05817214
- anti-PD-1 monoclonal antibodiesPhase 2 · NCT07623642
- ArtesunatePhase 2 · NCT07095478
- AtezolizumabPhase 2 · NCT03614949 · NCT06444815 · NCT07770100 · NCT05581004
- Avutometinib (VS-6766) + defactinibPhase 2 · NCT05512208
- B1962Phase 2 · NCT06724263
- BAY2927088Phase 2 · NCT06760819
- Becotatug Vedotin in combination with ZimberelimabPhase 2 · NCT07424664
- BelzutifanPhase 2 · NCT06677190
- BinimetinibPhase 2 · NCT02465060
- BL-B01D1Phase 2 · NCT07054567 · NCT05983432 · NCT05990803 · NCT05803018
- BNT327Phase 2 · NCT06953089
- Brachytherapy (BT)Phase 2 · NCT05799469
- Brachytherapy and External Beam RadiotherapyPhase 2 · NCT06419673 · NCT07232654
- CadonilimabPhase 2 · NCT05817214 · NCT06511726 · NCT06289751 · NCT07450963
- Cadonilimab combined with cisplatinPhase 2 · NCT07104149
- Cadonilimab（AK104）Phase 2 · NCT05687851
- Camrelizumab combined with chemotherapyPhase 2 · NCT07167160
- Cancer Therapeutic ProcedurePhase 2 · NCT07285044
- CapivasertibPhase 2 · NCT02465060
- Carboplatin (AUC 5)Phase 2 · NCT07811375 · NCT07876154
- Cediranib, OlaparibPhase 2 · NCT04487587
- CeralasertibPhase 2 · NCT04065269
- ChemoradiationPhase 2 · NCT05492123 · NCT06191133
- Chemoradiotherapy (small pelvic) + ZimberelimabPhase 2 · NCT05872724
- Chemoradiotherapy + Adjuvant chemotherapy and ZimberelimabPhase 2 · NCT05872724
- CilostazolPhase 2 · NCT06492070
- Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)Phase 2 · NCT04516616
- Cnidium Monnieri Detoxification FormulaPhase 2 · NCT06705322
- CobolimabPhase 2 · NCT06238635
- combination of relatlimab and nivolumab wich are two immunotherapy treatmentsPhase 2 · NCT06715241
- Concurrent chemo-radiotherapyPhase 2 · NCT07088731
- CONCURRENT CHEMORADIATION (CISPLATIN)Phase 2 · NCT07244965
- Concurrent chemoradiotherapyPhase 2 · NCT06511726
- Conventional Fractionated RadiotherapyPhase 2 · NCT07276360
- CopanlisibPhase 2 · NCT02465060
- Copanlisib HydrochloridePhase 2 · NCT02465060
- CrizotinibPhase 2 · NCT02465060
- Cryocompression TherapyPhase 2 · NCT06492070
- Curcumin C3 ComplexPhase 2 · NCT04266275
- CVL237 tabletsPhase 2 · NCT07446049
- Cytokine-induced killer cellsPhase 2 · NCT02490748
- DabrafenibPhase 2 · NCT02465060
- Dabrafenib MesylatePhase 2 · NCT02465060
- DasatinibPhase 2 · NCT02465060
- DB-1305/BNT325Phase 2 · NCT06953089
- DB-1311/BNT324Phase 2 · NCT06953089
- DefactinibPhase 2 · NCT02465060
- Defactinib HydrochloridePhase 2 · NCT02465060
- Definitive hypofractionated intensity-modulated radiation theraphyPhase 2 · NCT07439497
- Disitamab VedotinPhase 2 · NCT06155396
- DostarlimabPhase 2 · NCT06023862 · NCT06238635 · NCT07336147 · NCT04068753
- DoxorubicinPhase 2 · NCT06023862
- Drug: CisplatinPhase 2 · NCT06786780
- Drug: Drug: QL1706 5mg/kg, iv drip,d1,Q3W;Albumin-Bound Paclitaxel 260mg/m2, iv drip, d1, Q3W;Cisplatin50mg/m2, iv drip, d1, Q3W;Carboplatin AUC 5 ivdrip, d1, Q3WPhase 2 · NCT07286253
- DurvalumabPhase 2 · NCT04065269
- E7 TCR-T cellsPhase 2 · NCT05639972 · NCT05686226
- EBRT dose prescription and reportingPhase 2 · NCT03617133
- EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouringPhase 2 · NCT03617133
- Efbemalenograstim AlfaPhase 2 · NCT06251947
- Enlonstobart InjectionPhase 2 · NCT06981858
- EnvafolimabPhase 2 · NCT05799469
- ErdafitinibPhase 2 · NCT02465060
- External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy ExperimentalPhase 2 · NCT04583254
- External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of CarePhase 2 · NCT04583254
- External Beam Radiotherapy BoostPhase 2 · NCT07276360
- Famitinib + CamrelizumabPhase 2 · NCT07143292
- Famitinib MalatePhase 2 · NCT07627620
- FexagratinibPhase 2 · NCT02465060
- FulvestrantPhase 2 · NCT05768139 · NCT04579380
- Gemcitabine injectionPhase 2 · NCT06241781
- Granulocyte-Macrophage Colony-Stimulating FactorPhase 2 · NCT05817214
- GT101 injectionPhase 2 · NCT06241781
- GV20-0251Phase 2 · NCT07623642
- HAL 5% with illuminationPhase 2 · NCT07669363
- HER3-DXdPhase 2 · NCT06172478
- herombopagPhase 2 · NCT06745219
- High dose IL-2Phase 2 · NCT06630611
- High-Dose Rate BrachytherapyPhase 2 · NCT07276360 · NCT02595879
- high-dose-rate (HDR) brachytherapyPhase 2 · NCT06331468
- HLX43Phase 2 · NCT06769152
- HPV vaccine, Imiquimod, and metformin combination therapyPhase 2 · NCT06686043
- Human papillomavirus 9-valent vaccine, RecombinantPhase 2 · NCT06681636
- Hypofractionated EBRTPhase 2 · NCT04831437
- Hypofractionated Radiation TherapyPhase 2 · NCT07276360
- IL-2 analogPhase 2 · NCT06630611
- Increased use of IC/IS technique in BTPhase 2 · NCT03617133
- Intensity Modulated Proton Therapy (IMPT)Phase 2 · NCT07415681
- intensity modulated radiation therapy (IMRT)Phase 2 · NCT06331468
- intra-lesional boost IMRTPhase 2 · NCT07435376
- Iparomlimab and TuvonralimabPhase 2 · NCT06942416
- Iparomlimab and Tuvonralimab (QL1706)Phase 2 · NCT07646301
- Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapyPhase 2 · NCT06986057
- Iparomlimab/TuvonralimabPhase 2 · NCT07232654 · NCT07876154
- IpatasertibPhase 2 · NCT02465060
- IpilimumabPhase 2 · NCT06047379 · NCT07770100
- Ipilimumab 200 MG in 40 ML InjectionPhase 2 · NCT05492123
- IvonescimabPhase 2 · NCT06925724
- Ivonescimab Combined With ChemotherapyPhase 2 · NCT07244965
- LarotrectinibPhase 2 · NCT02465060
- Larotrectinib SulfatePhase 2 · NCT02465060
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101Phase 2 · NCT04580771
- loco-regional hyperthermiaPhase 2 · NCT04889742
- LorigerlimabPhase 2 · NCT05475171
- Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)Phase 2 · NCT06670911
- N-803 + AtezolizumabPhase 2 · NCT03228667
- N-803 + Atezolizumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + AvelumabPhase 2 · NCT03228667
- N-803 + Avelumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + Docetaxel + NivolumabPhase 2 · NCT03228667
- N-803 + Docetaxel + PembrolizumabPhase 2 · NCT03228667
- N-803 + DurvalumabPhase 2 · NCT03228667
- N-803 + Durvalumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + NivolumabPhase 2 · NCT03228667
- N-803 + Nivolumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + PembrolizumabPhase 2 · NCT03228667
- N-803 + Pembrolizumab + PD-L1 t-haNKPhase 2 · NCT03228667
- Nab-paclitaxelPhase 2 · NCT07763496 · NCT07876154
- neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cyclesPhase 2 · NCT07055399
- Neoadjuvant Chemotherapy (NACT)Phase 2 · NCT06916117
- Neoadjuvant Chemotherapy Combined with ImmunotherapyPhase 2 · NCT07130240
- Neoadjuvant immunochemotherapyPhase 2 · NCT07003620
- Nimotuzumab InjectionPhase 2 · NCT06771596
- Nimotuzumab、TislelizumabPhase 2 · NCT06039891
- NiraparibPhase 2 · NCT04068753
- NivolumabPhase 2 · NCT06638931 · NCT03589339 · NCT07576725 · NCT07653503 · NCT07223424 · NCT02465060 · NCT06047379 · NCT02257528 · NCT07770100
- Nivolumab 40 mg in 4 ml InjectionPhase 2 · NCT05492123
- NMA-LD regimenPhase 2 · NCT06630611
- Nonavalent HPV vaccine (9vHPV)Phase 2 · NCT07303751
- OlaparibPhase 2 · NCT04065269
- Online adaptive radiotherapyPhase 2 · NCT05869123 · NCT05880485 · NCT06562166
- OsimertinibPhase 2 · NCT02465060
- Paclitaxel and Cisplatin/ CarboplatinPhase 2 · NCT06942416
- Paclitaxel-albuminPhase 2 · NCT06288360 · NCT06289751
- PalbociclibPhase 2 · NCT05768139 · NCT02465060
- Pegylated liposomal doxorubicinPhase 2 · NCT06023862
- Pelvic External-Beam Radiotherapy (EBRT)Phase 2 · NCT07092696
- Pembrolizumab (KEYTRUDA®)Phase 2 · NCT05086692 · NCT06805864 · NCT04977453
- pembrolizumab and lenvatinibPhase 2 · NCT07368985
- PertuzumabPhase 2 · NCT02465060
- PI3K-beta Inhibitor GSK2636771Phase 2 · NCT02465060
- PrasteronePhase 2 · NCT07407647
- PRGN-2009 plus PembrolizumabPhase 2 · NCT06157151
- Proton therapyPhase 2 · NCT06462378
- QL1706Phase 2 · NCT07172217 · NCT07256236
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)Phase 2 · NCT07141186
- QL1706 + Cisplatin/Paclitaxel Neoadjuvant TherapyPhase 2 · NCT07617818
- QL1706+TCPhase 2 · NCT07205497
- Radiation treatmentPhase 2 · NCT05521997
- RC48Phase 2 · NCT07172217
- Reduction of vaginal source loadingPhase 2 · NCT03617133
- RelacorilantPhase 2 · NCT07763496
- RelatlimabPhase 2 · NCT02465060
- Romiplostim N01Phase 2 · NCT07586826
- RTPhase 2 · NCT07450963
- Sacituzumab govitecanPhase 2 · NCT05838521
- Sacituzumab tirumotecan plus IparomlimabPhase 2 · NCT07348861
- SapanisertibPhase 2 · NCT02465060
- SerplulimabPhase 2 · NCT06727617 · NCT07340489 · NCT06419673
- SHR-A1811 InjectionPhase 2 · NCT07051486
- SI-B003Phase 2 · NCT05990803
- SintilimabPhase 2 · NCT07088731
- SpartalizumabPhase 2 · NCT04802876
- Standard EBRTPhase 2 · NCT04831437
- Stereotactic body radiation therapy (SBRT)Phase 2 · NCT03614949 · NCT07770100
- Sunitinib MalatePhase 2 · NCT02465060
- Systematic utilisation of IMRTPhase 2 · NCT03617133
- Systemic application of simultaneous chemotherapyPhase 2 · NCT03617133
- TaselisibPhase 2 · NCT02465060
- TelaglenastatPhase 2 · NCT05521997
- TislelizumabPhase 2 · NCT04802876 · NCT05238883 · NCT05511623
- ToripalimabPhase 2 · NCT06416696 · NCT07092696
- TrametinibPhase 2 · NCT02465060
- trastuzumabPhase 2 · NCT04579380 · NCT02465060 · NCT05081609
- Trastuzumab EmtansinePhase 2 · NCT02465060
- Trastuzumab RezetecanPhase 2 · NCT07631884
- Trial drug: QL1706, HPV 9-valent vaccinePhase 2 · NCT06882447
- Trilaciclib InjectionPhase 2 · NCT06297811
- TSR-042Phase 2 · NCT03833479
- tucatinibPhase 2 · NCT04579380
- Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusionPhase 2 · NCT06630611
- UlixertinibPhase 2 · NCT02465060
- Utidelone plus ToripalimabPhase 2 · NCT07363330
- Utilisation of daily IGRT (set-up according to bony structures)Phase 2 · NCT03617133
- VismodegibPhase 2 · NCT02465060
- Volume Modulated Arc Therapy (VMAT)Phase 2 · NCT07415681
- vudalimabPhase 2 · NCT05032040
- Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)Phase 2 · NCT05758688
- YL202Phase 2 · NCT07202364
- ZanidatamabPhase 2 · NCT07631871
- ZimberelimabPhase 2 · NCT05824468 · NCT05891171 · NCT06128460 · NCT06155396 · NCT06055738
- 177Lu-BetaBartPhase 1/2 · NCT07189871
- AbemaciclibPhase 1/2 · NCT05768139
- AbirateronePhase 1/2 · NCT05914116
- Adebelimab injectionPhase 1/2 · NCT06859775
- Albumin-Bound Paclitaxel, cisplatin, SintilimabPhase 1/2 · NCT06391190
- Alendronate 70mg weeklyPhase 1/2 · NCT07245381
- AnastrozolePhase 1/2 · NCT05768139
- Anti-PD-1 monoclonal antibodyPhase 1/2 · NCT05941507
- ARV-6723Phase 1/2 · NCT07749586
- ASTX660Phase 1/2 · NCT02503423 · NCT05082259
- AvelumabPhase 1/2 · NCT03260023
- AZD5305Phase 1/2 · NCT04644068
- BetaBart + unlabeled BetaBartPhase 1/2 · NCT07189871
- BMS-936558-01Phase 1/2 · NCT04895709
- BMS-986340Phase 1/2 · NCT04895709
- CamizestrantPhase 1/2 · NCT04644068
- Carbon Nanoparticle-Loaded IronPhase 1/2 · NCT07433283
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe]Phase 1/2 · NCT07433283
- Chemotherapy drugPhase 1/2 · NCT05081609
- Coenzyme Q10 Cap/TabPhase 1/2 · NCT07668284
- Concurrent Radiation TherapyPhase 1/2 · NCT06814496
- CR-002Phase 1/2 · NCT07909031
- CyclophosphamidePhase 1/2 · NCT05269381 · NCT06505551
- Dato-DXdPhase 1/2 · NCT04644068
- DB-1311Phase 1/2 · NCT05914116
- Distilled water groupPhase 1/2 · NCT06672653
- Docetaxel (Taxotere)Phase 1/2 · NCT05592626
- EnzalutamidePhase 1/2 · NCT05914116
- ErythromycinPhase 1/2 · NCT05579366
- ETX-636 dose escalationPhase 1/2 · NCT06993844
- ETX-636 dose escalation in combination with fulvestrantPhase 1/2 · NCT06993844
- ETX-636 dose expansion in combination with fulvestrantPhase 1/2 · NCT06993844
- ExemestanePhase 1/2 · NCT05768139
- FilgrastimPhase 1/2 · NCT07064018
- FludarabinePhase 1/2 · NCT06505551
- FOLFIRI ProtocolPhase 1/2 · NCT06047379
- Fulvestrant injectionPhase 1/2 · NCT07109726
- GecacitinibPhase 1/2 · NCT07080216
- GI-101Phase 1/2 · NCT04977453
- GI-101APhase 1/2 · NCT04977453
- GM103 (Part A)Phase 1/2 · NCT06265025
- GM103 (Part B)Phase 1/2 · NCT06265025
- GM103 and Pembrolizumab (Part C)Phase 1/2 · NCT06265025
- HMBD-001Phase 1/2 · NCT05057013
- HMBD-001 and enzalutamidePhase 1/2 · NCT05057013
- HTL0039732 CapsulesPhase 1/2 · NCT05944237
- HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusionPhase 1/2 · NCT05944237
- Hypofractionated external beam radiationPhase 1/2 · NCT06529809
- HypofractionationPhase 1/2 · NCT05210270
- IDP-001Phase 1/2 · NCT07602842
- Ifinatamab deruxtecanPhase 1/2 · NCT06330064
- Image-guided brachytherapyPhase 1/2 · NCT06529809
- ImlunestrantPhase 1/2 · NCT05768139
- ipilimumab +pembrolizumab +durvalumabPhase 1/2 · NCT05187338
- Irinotecan (Camptosar)Phase 1/2 · NCT05592626
- ItraconazolePhase 1/2 · NCT05579366 · NCT06400472 · NCT05914116
- LCB84Phase 1/2 · NCT05941507
- LetrozolePhase 1/2 · NCT05768139
- Lopinavir and Ritonavir TabletsPhase 1/2 · NCT05914116
- MDNA11Phase 1/2 · NCT05086692
- MDX2001Phase 1/2 · NCT06239194
- MetforminPhase 1/2 · NCT05768139
- Module 1 (GRWD5769 on its own as monotherapy)Phase 1/2 · NCT06923761
- Module 2 (GRWD5769 in combination with cemiplimab, administered IV)Phase 1/2 · NCT06923761
- MT-4561Phase 1/2 · NCT06943521
- NEO-201 in combination with pembrolizumabPhase 1/2 · NCT03476681
- NEO212 Oral CapsulePhase 1/2 · NCT06047379
- Neoantigen Peptide VaccinePhase 1/2 · NCT05269381
- ONC-392Phase 1/2 · NCT04140526
- One IM injection Lenti-HPV-07Phase 1/2 · NCT06319963
- PegfilgrastimPhase 1/2 · NCT07064018
- Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical CancerPhase 1/2 · NCT07206563
- PumitamigPhase 1/2 · NCT04895709
- Q702Phase 1/2 · NCT05438420
- RegorafenibPhase 1/2 · NCT06047379
- RibociclibPhase 1/2 · NCT05768139
- Rina-SPhase 1/2 · NCT05579366
- SargramostimPhase 1/2 · NCT05269381
- SCG142Phase 1/2 · NCT06505551
- Sequential Radiation therapyPhase 1/2 · NCT06814496
- SHR-8068Phase 1/2 · NCT06859775
- SHR-A1811Phase 1/2 · NCT06859775
- SKB264Phase 1/2 · NCT04152499
- Spedox-6Phase 1/2 · NCT07064018
- STAR0602Phase 1/2 · NCT05592626
- STX-478Phase 1/2 · NCT05768139
- T- DxdPhase 1/2 · NCT04644068
- TamoxifenPhase 1/2 · NCT05768139
- TarlatamabPhase 1/2 · NCT06814496
- TER-2013Phase 1/2 · NCT07109726
- TG4001Phase 1/2 · NCT03260023
- The monoterpenoid zinc tetra-ascorbo-camphorate ("C14")Phase 1/2 · NCT06672653
- TransCon IL-2 β/γPhase 1/2 · NCT05081609
- TransCon TLR7/8 AgonistPhase 1/2 · NCT05081609
- Trastuzumab emtansine (T-DM1)Phase 1/2 · NCT05081609
- Two IM injections Lenti-HPV-07Phase 1/2 · NCT06319963
- UCB4594Phase 1/2 · NCT06380816
- Vitamin E Cap/TabPhase 1/2 · NCT07668284
- XNW28012Phase 1/2 · NCT06799637
- YH32364Phase 1/2 · NCT06975410
- ZG005Phase 1/2 · NCT07080216
- ZG005 for InjectionPhase 1/2 · NCT06938880
- ZGGS18 for InjectionPhase 1/2 · NCT06938880
- ²¹²Pb-DOTAM-GRPR1Phase 1 · NCT05283330
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid TumorsPhase 1 · NCT06508307
- AB598Phase 1 · NCT05891171
- ADRX-0706Phase 1 · NCT06036121
- Alpaloritovorelli antibodiesPhase 1 · NCT06760676
- ALTA2618Phase 1 · NCT06533059
- ATV-1601Phase 1 · NCT07038369
- ATV-1601 + FulvestrantPhase 1 · NCT07038369
- Autologous tumor infiltrating lymphocytes (TILs)Phase 1 · NCT05366478
- Barrigel gel spacerPhase 1 · NCT07292818
- BL-M07D1Phase 1 · NCT06293898
- CD70 CAR-T cellsPhase 1 · NCT05518253 · NCT06215950
- CemiplimabPhase 1 · NCT06022029
- cetuximabPhase 1 · NCT04485013
- CHT101Phase 1 · NCT06383507
- CRTE7A2-01 TCR-T cell therapyPhase 1 · NCT06358053
- DR-0202Phase 1 · NCT06999187
- ElimusertibPhase 1 · NCT04491942
- EnzelkitugPhase 1 · NCT05581004
- FenofibratePhase 1 · NCT06191133
- FF-10850 Topotecan Liposome InjectionPhase 1 · NCT04047251
- FluBHPVE6E7Phase 1 · NCT05829629
- Fludarabine + CyclophosphamidePhase 1 · NCT05952947
- FluorouracilPhase 1 · NCT05891171
- FOLFIRIPhase 1 · NCT04485013
- Gemcitabine HydrochloridePhase 1 · NCT04491942
- HC010Phase 1 · NCT06307925
- HFB200301Phase 1 · NCT05238883
- HH160Phase 1 · NCT07623369
- HRYZ-T101 InjectionPhase 1 · NCT05952947
- IDOV-Immune (oncolytic vaccinia virus)Phase 1 · NCT06910657
- IMGN151Phase 1 · NCT05527184
- IPH4502Phase 1 · NCT06781983
- KD01(the recombinant oncolytic adenovirus)Phase 1 · NCT06552598
- KIVU-107Phase 1 · NCT07229313
- KK-LC-1 TCR-T cellsPhase 1 · NCT05483491
- KRC-01Phase 1 · NCT05570422
- LeucovorinPhase 1 · NCT05891171
- LoperamidePhase 1 · NCT04038619
- LY4052031Phase 1 · NCT06465069
- LY4101174Phase 1 · NCT06238479
- MGC026 Dose EscalationPhase 1 · NCT06242470
- MGC026 Dose for ExpansionPhase 1 · NCT06242470
- MT-302 (A)Phase 1 · NCT05969041
- Nanocrystalline Megestrol Acetate Oral SuspensionPhase 1 · NCT07338487
- NBTXR3Phase 1 · NCT03589339
- NRM-823Phase 1 · NCT07182149
- NX-1607Phase 1 · NCT05107674
- ONM-501Phase 1 · NCT06022029
- OxaliplatinPhase 1 · NCT05891171
- PembrollizumabPhase 1 · NCT06242470
- PLDR+CardunizumabPhase 1 · NCT06232083
- Pulsed low dose rate radiotherapy (PLDR)Phase 1 · NCT06760676
- PVX7Phase 1 · NCT06315257
- RGT-490Phase 1 · NCT07524322
- RNDO-564Phase 1 · NCT07218003
- SABRPhase 1 · NCT03589339
- SCG142 TCR-T cellsPhase 1 · NCT06544720
- sigvotatug vedotinPhase 1 · NCT04389632
- Sofe-MPhase 1 · NCT06400472
- STRO-004Phase 1 · NCT07227168
- TalazoparibPhase 1 · NCT03968406
- therapeutic tumor vaccinePhase 1 · NCT07081984
- TSC-200-A0201Phase 1 · NCT05973487
- TSC-200-A0201 + TSC-201-B0702Phase 1 · NCT05973487
- TSC-200-A0201 + TSC-202-A0201Phase 1 · NCT05973487
- TSC-200-A0201 + TSC-203-A0201Phase 1 · NCT05973487
- TSC-200-A0201 + TSC-204-A0101Phase 1 · NCT05973487
- TSC-201-B0702Phase 1 · NCT05973487
- TSC-201-B0702 + TSC-202-A0201Phase 1 · NCT05973487
- TSC-202-A0201Phase 1 · NCT05973487
- TSC-203-A0201Phase 1 · NCT05973487
- TSC-203-A0201 + TSC-201-B0702Phase 1 · NCT05973487
- TSC-203-A0201 + TSC-202-A0201Phase 1 · NCT05973487
- TSC-203-A0201 + TSC-204-A0101Phase 1 · NCT05973487
- TSC-204-A0101Phase 1 · NCT05973487
- TSC-204-A0101 + TSC-202-A0201Phase 1 · NCT05973487
- TSC-204-A0201Phase 1 · NCT05973487
- TSC-204-A0201 + TSC-200-A0201Phase 1 · NCT05973487
- TSC-204-A0201 + TSC-201-B0702Phase 1 · NCT05973487
- TSC-204-A0201 + TSC-202-A0201Phase 1 · NCT05973487
- TSC-204-A0201 + TSC-203-A0201Phase 1 · NCT05973487
- TSC-204-A0201 + TSC-204-A0101Phase 1 · NCT05973487
- TSC-204-A0201 + TSC-204-C0702Phase 1 · NCT05973487
- TSC-204-C0702Phase 1 · NCT05973487
- TSC-204-C0702 + TSC-200-A0201Phase 1 · NCT05973487
- TSC-204-C0702 + TSC-201-B0702Phase 1 · NCT05973487
- TSC-204-C0702 + TSC-202-A0201Phase 1 · NCT05973487
- TSC-204-C0702 + TSC-203-A0201Phase 1 · NCT05973487
- TSC-204-C0702 + TSC-204-A0101Phase 1 · NCT05973487
- TTX-080Phase 1 · NCT04485013
- VET3-TGIPhase 1 · NCT06444815
- vobramitamab tavatecanPhase 1 · NCT06242470
- [177Lu]Lu-AKIR001Early phase 1 · NCT06639191
- GadobutrolEarly phase 1 · NCT04219904
- Metabolically Armed TIL cellsEarly phase 1 · NCT07106814
Closest to patients
- Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine CancerPhase 3 trial: Gemcitabine, CisplatinNational Cancer Institute of Mexico · Mexico City, MexicoPhase 3Results expected 2026
- Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical CancerPhase 3 trial: cisplatin, gemcitabineHospital Santa Marcelina · São Paulo, Brazil + 25 more hospitalsPhase 3Results expected 2026
- Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY TrialPhase 3 trial: HPV vaccine, HAV vaccineInternational Agency for Research on Cancer (sponsor)Phase 3Results expected 2027
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
A Multilingual AI-Driven Conversational System for Cervical Cancer Awareness and Risk Assessment: Development and Evaluation Study.
A Multilingual AI-Driven Conversational System for Cervical Cancer Awareness and Risk Assessment: Development and Evaluation Study.
JMIR cancer
PubMed · PMID 42993957Publication
Comments with 'Cross-country inequalities and frontier analysis in global burden of cervical cancer: cross-sectional studies'.
Comments with 'Cross-country inequalities and frontier analysis in global burden of cervical cancer: cross-sectional studies'.
Journal of gynecologic oncology
PubMed · PMID 42989934Preprint
Utilizing a Variant Prioritization Approach to Explore Genetic Variants in Cervical Cancer Cases among Malawian Women.
Utilizing a Variant Prioritization Approach to Explore Genetic Variants in Cervical Cancer Cases among Malawian Women.
medRxiv : the preprint server for health sciences
PubMed · PMID 42990339Publication
[A Multicenter Retrospective Investigation of the Distribution of High-Risk HPV Genotypes Among Women Who Underwent HPV Testing in Azerbaijan].
[A Multicenter Retrospective Investigation of the Distribution of High-Risk HPV Genotypes Among Women Who Underwent HPV Testing in Azerbaijan].
Mikrobiyoloji bulteni
PubMed · PMID 42992492Publication
A comprehensive assessment of cervical cancer risk factors, screening modalities, and cytological outcomes.
A comprehensive assessment of cervical cancer risk factors, screening modalities, and cytological outcomes.
JPMA. The Journal of the Pakistan Medical Association
PubMed · PMID 42989660
Organisations that can help
Helplines, patient groups and support services for you and your family.
Select your country to see the organisations there, starting with the ones closest to you.
Umbrella organisations (they connect national groups)
ENGAGe - European Network of Gynaecological Cancer Advocacy Groups (ESGO)
ESGO network of 80+ gynaecological cancer patient groups; member list with country filter.
Visit site: ENGAGe - European Network of Gynaecological Cancer Advocacy Groups (ESGO)European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
Visit site: European Cancer Patient Coalition (ECPC)
International Gynecologic Cancer Advocacy Network
Advocacy network of the International Gynecologic Cancer Society: annual advocacy summit, education, advocacy directory; free patient education for survivors and carers
Visit site: International Gynecologic Cancer Advocacy Network
General support
For anyone who is ill, whatever the disease: patients' rights and legal aid, crisis lines, hospice and palliative care, care in another EU country, and patient organisations' umbrella bodies.
International
European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)
International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Cervical cancer work.
The University of Texas MD Anderson Cancer Center
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Fujian Medical University
Fuzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Huazhong University of Science and Technology
Wuhan, China
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Agostino Gemelli University Polyclinic
Rome, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Nanjing Medical University
Nanjing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it